This week’s View features a number of updates on a variety of issues related to transcatheter aortic valve replacement (TAVR). This includes a look at whether it makes sense to expand the use of TAVR to younger patients, an analysis of whether increasing operator experience contributes to better outcomes, and a discussion of whether TAVR can be used successfully “off-label.”